Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

11/7/24 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $EXEL alert in real time by email

- Presentations to be webcast on www.exelixis.com -

Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:

Guggenheim's Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston.
Stifel 2024 Healthcare Conference: Exelixis is scheduled to present at 10:20 a.m. ET / 7:20 a.m. PT on Monday, November 18 in New York City.
Jefferies London Healthcare Conference: Exelixis is scheduled to present at 10:30 a.m. BST / 5:30 a.m. ET / 2:30 a.m. PT on Tuesday, November 19 in London, UK.

To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107742591/en/

Get the next $EXEL alert in real time by email

Recent Analyst Ratings for

$EXEL

Date	Price Target	Rating	Analyst
10/16/2024	$30.00 → $34.00	Outperform	RBC Capital Mkts
9/19/2024	$30.00	Neutral	UBS
4/11/2024	$25.00	Overweight → Equal Weight	Barclays
12/19/2023	$27.00	Buy	BTIG Research
12/15/2023	$31.00	Buy	Citigroup
9/26/2023	$28.00	Buy	H.C. Wainwright
8/22/2023	$25.00 → $29.00	Outperform	Oppenheimer
8/8/2023	$18.00	Market Perform	SVB Securities

More analyst ratings

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Chat with this insight

Recent Analyst Ratings for $EXEL

$EXEL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP and CFO Senner Christopher J. covered exercise/tax liability with 17,506 shares, decreasing direct ownership by 2% to 704,174 units (SEC Form 4)

President and CEO Morrissey Michael covered exercise/tax liability with 47,642 shares, decreasing direct ownership by 5% to 916,742 units (SEC Form 4)

EVP & General Counsel Hessekiel Jeffrey covered exercise/tax liability with 14,672 shares, decreasing direct ownership by 3% to 515,653 units (SEC Form 4)

$EXEL Press Releases

Fastest customizable press release news feed in the world

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

$EXEL SEC Filings

SEC Form 10-Q filed by Exelixis Inc.

Exelixis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Exelixis Inc. filed SEC Form 8-K: Other Events

$EXEL Market Insights

Live Market Insights

10 Health Care Stocks Whale Activity In Today's Session

Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying

Exelixis Settles With Cipla To Resolve Two Patent Litigation; Grants Cipla License To Market Generic Versions Of CABOMETYX On Jan 1, 2031 If Approved By FDA And Subject To Conditions; Parties Terminate All Hatch-Waxman Litigation Regarding CABOMETYX

$EXEL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

RBC Capital Mkts reiterated coverage on Exelixis with a new price target

UBS initiated coverage on Exelixis with a new price target

Exelixis downgraded by Barclays with a new price target

$EXEL Leadership Updates

Live Leadership Updates

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

$EXEL Financials

Live finance-specific insights

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update

$EXEL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

SEC Form SC 13G filed by Exelixis Inc.

SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

$EXEL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

$EXEL FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for CABOMETYX issued to EXELIXIS INC

FDA Approval for CABOMETYX issued to EXELIXIS INC

FDA Approval for CABOMETYX issued to EXELIXIS INC

Recent Analyst Ratings for
$EXEL

$EXEL
Insider Trading

$EXEL
Press Releases

$EXEL
SEC Filings

$EXEL
Market Insights

$EXEL
Analyst Ratings

$EXEL
Leadership Updates

$EXEL
Financials

$EXEL
Large Ownership Changes

$EXEL
Insider Purchases

$EXEL
FDA approvals